CLAIM AMENDMENTS

Please amend the claims as follows:

1. (currently amended): A compound of formula I



I

or pharmaceutically acceptable ~~prodrugs,~~ salts~~, hydrates, solvates, crystal forms~~ or diastereomers thereof, wherein:

A is ~~selected from O, S, and~~ NR^1, where R^1 is H, or C_{1-4} alkyl;

B is ~~aryl, or hetaryl~~ phenyl optionally substituted ~~with 0-3~~ with 0-4 substituents independently selected from halogen, C_{1-4} alkyl, CF_3, CN, aryl, ~~hetaryl,~~ OH, OCF_3, OC_{1-4} alkyl, OC_{2-5} alkylNR^2R^3, Oaryl, ~~Ohetaryl,~~ CO_2R^2, $CONR^2R^3$, NR^2R^3, ~~C_{1-4} alkylNR^2R^3,~~ NR^4C_{1-4} alkylNR^2R^3, NR^2COR^3, $OC(O)NR^2R^3$, $NR^4CONR^2R^3$, and $NR^2SO_2R^3$;

wherein R^2, R^3 are each independently H, C_{1-4} alkyl, ~~C_{1-4} alkyl heterocyclyl,~~ aryl, ~~hetaryl,~~ C_{1-4} alkyl aryl, ~~C_{1-4} alkyl hetaryl,~~ or may be joined to form an optionally substituted 3-8 membered ring optionally containing one of O, S, or NR^5;

wherein R^4 is H or C_{1-4} alkyl; and

wherein R^5 is H or C_{1-4} alkyl;

Q is a bond when W is absent, and is C_{1-4} alkyl when W is present;

W is selected from H, C_{1-4} alkyl, C_{2-6} alkenyl; where C_{1-4} alkyl or C_{2-6} alkenyl may be optionally substituted with C_{1-4} alkyl, OH, OC_{1-4} alkyl, $NR^6C(O)R^7$, $CONR^6R^7$, OR^6, or NR^6R^7;

wherein R^6, and R^7 are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cycloalkyl, ~~C_{1-4} alkyl heterocyclyl,~~ aryl, ~~hetaryl,~~ or may be joined to form an optionally substituted 3-8 membered ring ~~optionally containing one of O, S, or NR^8~~, and

~~wherein R^8 is H, or C_{1-4} alkyl;~~

Y is H or phenyl, ~~aryl or hetaryl~~ optionally substituted with 0-3 substituents independently selected from halogen, C_{1-4} alkyl, CF_3, aryl, ~~hetaryl,~~ OH, OCF_3, CN, C_{2-4} alkynyl, OC_{1-4} alkyl,

OC_{2-5} alkylNR^9R^{10}, Oaryl, ~~Ohetaryl,~~ CO_2R^9, $CONR^9R^{10}$, NR^9R^{10}, C_{1-4} alkylNR^9R^{10}, $NR^{11}C_{1-4}$ alkylNR^9R^{10}, NR^9COR^{10}, $NR^{11}CONR^9R^{10}$, and $NR^9SO_2R^{10}$;

wherein R^9 and R^{10} is each independently H, C_{1-4} alkyl, ~~C_{1-4} alkyl heterocyclyl,~~ aryl, ~~hetaryl,~~ C_{1-4} alkyl aryl, ~~C_{1-4} alkyl hetaryl,~~ or may be joined to form an optionally substituted 3-8 membered ring ~~optionally containing one O, S, or NR^{12}~~;

wherein R^{11} is H or C_{1-4} alkyl; ~~and R^{12} is H or C_{1-4} alkyl~~

with the proviso that when Y is phenyl substituted at the ortho position with CO_2R^9, CN or NH_2, W is absent and Q is a bond, and B has one or zero substituents, then R^1 is C_{1-4} alkyl.

2. (currently amended): A compound according to claim 1 or pharmaceutically acceptable ~~prodrugs,~~ salts~~, hydrates, solvates, crystal forms~~ or diastereomers thereof, wherein:

~~A is NR^+ and R^+ is H or C_{1-4} alkyl;~~

W is selected from H, C_{1-4} alkyl, and C_{2-6} alkenyl; ~~where~~ wherein C_{1-4} alkyl or C_{2-6} alkenyl may be optionally substituted with C_{1-4} alkyl, OH, OC_{1-4} alkyl, or NR^6R^7;

wherein R^6, and R^7 are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cycloalkyl, ~~C_{1-4} alkyl heterocyclyl,~~ aryl, ~~hetaryl,~~ or may be joined to form an optionally substituted 3-8 membered ring ~~optionally containing one of O, S or NR^8~~;

~~wherein R^8 is H or C_{1-4} alkyl;~~

Y is H or phenyl~~, aryl or hetaryl~~ optionally substituted with 0-3 substituents independently selected from halogen, C_{1-4} alkyl, CF_3, aryl, ~~hetaryl,~~ OH, OCF_3, OC_{1-4} alkyl, OC_{2-5} alkylNR^9R^{10}, Oaryl, ~~Ohetaryl,~~ CO_2R^9, $CONR^9R^{10}$, NR^9R^{10}, C_{1-4} alkylNR^9R^{10}, $NR^{11}C_{1-4}$ alkylNR^9R^{10}, NR^9COR^{10}, $NR^{11}CONR^9R^{10}$, and $NR^9SO_2R^{10}$;

wherein R^9, and R^{10} are each independently H, C_{1-4} alkyl, ~~C_{1-4} alkyl heterocyclyl,~~ aryl, ~~hetaryl,~~ C_{1-4} alkyl aryl, ~~C_{1-4} alkyl hetaryl,~~ or may be joined to form an optionally substituted 3-8 membered ring ~~optionally containing an atom selected from one of O, S, NR12~~; and ~~R11 is selected from H, or NR^{12}; and~~

wherein R^{11} is H or C_{1-4} alkyl~~; and R12 is selected from H, R^{12} is H or C_{1-4} alkyl~~.

3. (currently amended): A compound according to claim 1 wherein the compound is selected from the group consisting of:



C22H22N2O4



C23H23ClN2O4



C20H18N2O2



C22H20ClFN2O4



C19H15FN2O2



C22H20ClFN2O4



C19H16N2O2



C22H21ClN2O4



C20H19N3O2



C20H16N2O3



C23H24N2O4



C16H12N2OS



C21H19FN2O2



C18H16N2OS



C19H18N2O3



C13H14N2OS



C22H22N2O2



C18H16N2OS



C21H19FN2O2



C20H19N3O2S



C21H20N2O2



C17H13FN2OS



C17H13FN2OS



C21H20N2O2



C18H16N2OS



C21H20N2O2



C20H20N2OS



C22H22N2O3



C17H14N2OS



C21H20N2O2



C18H15FN2OS



C20H17FN2O2



C19H17N3O3



C20H17FN2O2



C19H17N3O2



C20H18N2O2



C19H16N2O2



C21H20N2O3



C22H22N2O4



C20H17FN2O3



C18H16N2O3



C20H17FN2O3



C21H20N2O3



C20H18N2O3

or pharmaceutically acceptable ~~prodrugs,~~ salts~~, hydrates, solvates, crystal forms~~ or diastereomers thereof.

4. (currently amended): A pharmaceutical composition comprising a carrier and at least one compound of claim 1.

5-6. (canceled)

7. (new): A pharmaceutical composition comprising a carrier and at least one compound of claim 2.

8. (new): A pharmaceutical composition comprising a carrier and at least one compound of claim 3.